Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Silexion Therapeutics Corp (SLXN) had Return on Tangible Equity of -457.63% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-11.91M |
|
-- |
|
-- |
|
$11.63M |
|
$-11.63M |
|
$-0.28M |
|
$-11.91M |
|
$-11.91M |
|
$-11.91M |
|
$-11.91M |
|
$-11.91M |
|
$-11.91M |
|
$-11.63M |
|
$-11.62M |
|
1.33M |
|
1.33M |
|
$-8.96 |
|
$-8.96 |
|
| Balance Sheet Financials | |
$6.64M |
|
$0.03M |
|
$0.58M |
|
$7.21M |
|
$2.76M |
|
$1.57M |
|
$1.85M |
|
$4.61M |
|
$2.60M |
|
$2.60M |
|
$2.60M |
|
3.13M |
|
| Cash Flow Statement Financials | |
$-10.82M |
|
$-0.01M |
|
$15.64M |
|
$1.27M |
|
$6.08M |
|
$4.80M |
|
$0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.41 |
|
-- |
|
-- |
|
0.38 |
|
0.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.83M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-457.63% |
|
|
Return on Tangible Equity |
-457.63% |
-165.10% |
|
-285.59% |
|
$0.83 |
|
$-8.14 |
|
$-8.14 |
|